Karolinska Institute biologist receives 2016 Naomi Berrie Award for excellence in diabetes research

Nov 23 2016

Columbia University has awarded the 2016 Naomi Berrie Award for Outstanding Achievement in Diabetes Research to Peter Arner, MD, PhD, a Distinguished Professor in the Department of Medicine at the Karolinska Institute, whose studies on the turnover of fat tissue in the human body has revealed processes that contribute to obesity and diabetes.

The Naomi Berrie Award for Outstanding Achievement is Columbia University's top honor for excellence in diabetes research, and Dr. Arner is the 18th winner since the award's inception in 1999. Dr. Arner received the award on November 19 at a ceremony which took place at the Frontiers in Diabetes Research Symposium in the Russ Berrie Medical Science Pavilion at Columbia University Medical Center (CUMC).

"Peter has been responsible for identifying some of the key molecules, genes, and pathways that influence the production of fat cells and their growth," said Rudolph L. Leibel, MD, the Christopher J. Murphy Memorial Professor of Diabetes Research, co-director of the Naomi Berrie Diabetes Center, and chair of the award selection committee. "These discoveries have had a major impact on how we understand the role of body fat in metabolic diseases."

Dr. Arner and his collaborators were the first to show that the human body continues to produce fat cells into adulthood. Dr. Arner's team developed a method of measuring fat cell turnover in adults, which led to the discovery that fat cells are renewed relatively rapidly--around 8 percent of adult fat cells die every year and are replaced by new ones. Fat turnover was the same for all individuals in the study, including those who had lost a significant amount of weight, showing that the volume of fat cells, not their abundance, that causes body mass to rise and fall during a lifetime.

Dr. Arner is also credited with discovering several adipokines--molecules released from fat tissue that can trigger inflammation and regulate the size and number of fat cells. His group showed that a molecule called Tumor Necrosis Factor alpha (TNFα) alters the levels of leptin, a hormone secreted from fat that plays a critical role in the regulation of body weight.

In the clinic, Dr. Arner's group designed and conducted a clinical trial of the drug ibertesan, showing that it slowed the progression of neuropathy--a type of nerve damage that develops in 40 per cent of type 2 diabetes patients.

Peter Arner studied medicine at the Karolinska Institute, and received specialty training in internal medicine and in Endocrinology.

Source: Columbia University Medical Center